Education
About Us
Working with TipRanks
Follow Us
Savara (SVRA)
NASDAQ:SVRA
SVRA Stock Chart & Stats
$5.82
$0.04(1.15%)
At close: 4:00 PM EST
$5.82
$0.04(1.15%)
Day’s Range― - ―
52-Week Range$1.89 - $7.01
Previous CloseN/A
Volume189.20K
Average Volume (3M)2.71M
Market Cap
$1.18B
Enterprise Value$678.21M
Total Cash (Recent Filing)$124.39M
Total Debt (Recent Filing)$29.83M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Mar 26, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding203,467,850
10 Day Avg. Volume1,588,352
30 Day Avg. Volume2,711,080
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)3.55
Price to Sales (P/S)0.00
P/FCF Ratio-6.83
Enterprise Value/Market Cap0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-498.69
Enterprise Value/Ebitda-5.77
Forecast
1Y Price Target
$10.17Price Target Upside74.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.41
Revenue Forecast (FY)$14.01M
Bulls Say, Bears Say
Bulls Say
Clinical EvidencePhase 3 data published in a leading medical journal showed strong safety, durable clinical benefit, and achievement of primary endpoints, supporting broad therapeutic potential across disease severities.
Manufacturing De‑riskingResubmission with an established drug substance manufacturer and regulator alignment on analytical comparability meaningfully reduces chemistry and manufacturing risk for the application.
Regulatory MomentumPriority Review request for MOLBREEVI combined with a strengthened submission package increases the likelihood of an accelerated regulatory decision and a clearer approval pathway.
Bears Say
Payer Access And AffordabilityInsurance denials and potential high out‑of‑pocket costs may restrict patient access and slow commercial adoption even if clinical demand exists.
Residual Regulatory RiskA prior Refusal to File citing insufficient manufacturing data underscores ongoing regulatory risk until the agency fully accepts the resubmission.
Treatment ParadigmWhole lung lavage remains the standard initial therapy for severe cases, which could limit immediate first‑line uptake of the new drug despite its benefits.
Savara News
SVRA FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was $1.89 and its highest was $7.00 in the past 12 months.
What is Savara’s market cap?
Savara’s market cap is $1.18B.
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is Mar 26, 2026 which is in 67 days.
How were Savara’s earnings last quarter?
Savara released its earnings results on Nov 12, 2025. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.132 by -$0.008.
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -0.12.
How many shares outstanding does Savara have?
Savara has 203,467,850 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Savara reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.132. Following the earnings report the stock price went up 3.398%.
Which hedge fund is a major shareholder of Savara?
Currently, no hedge funds are holding shares in SVRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Savara Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Price Target Potential
76.26% Upside
Analyst Consensus
Strong Buy
Average Price Target:
$10.17 (74.74% Upside)
$10.17 (74.74% Upside)
Blogger Sentiment
Bullish
SVRA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $121.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
-78.74%
Trailing 12-Months
Asset Growth
-40.99%
Trailing 12-Months
Company Description
Savara
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
SVRA Stock 12 Month Forecast
Average Price Target
$10.17
▲(74.74% Upside)
Technical Analysis
Ownership Overview
12.06% Insiders
6.60% Mutual Funds
58.43% Other Institutional Investors
13.58% Public Companies and
Individual Investors